机构:[1]Boehringer Ingelheim Corporation, Ontario, Canada[2]Leiden University Medical Center, Leiden, Netherlands[3]University of Birmingham, Birmingham, United Kingdom[4]University Hospital of Essen (Ruhr), Essen, Germany[5]Clinic and Maternity Suizo Argentina, Buenos Aires, Argentina[6]Mount Sinai School of Medicine, New York,[7]RTI Health Solutions, Durham, United States of America[8]Beijing Anzhen Hospital, Beijing, China People’s Republic of首都医科大学附属安贞医院[9]Boehringer Ingelheim Corporation, Ridgefield, CT, United States of America[10]Boehringer Ingelheim International GmbH, Ingelheim, Germany[11]McMaster University, Hamilton, Canada
M.Paquette,M.V.Huisman,G.Y.H.Lip,et al.When are atrial fibrillation patients at risk to discontinue anticoagulation treatment? Results from the GLORIA-AF Registry[J].EUROPEAN HEART JOURNAL.2018,39:1007-1007.
APA:
M.Paquette,M.V.Huisman,G.Y.H.Lip,H.C.Diener,S.J.Dubner...&R.Nieuwlaat.(2018).When are atrial fibrillation patients at risk to discontinue anticoagulation treatment? Results from the GLORIA-AF Registry.EUROPEAN HEART JOURNAL,39,
MLA:
M.Paquette,et al."When are atrial fibrillation patients at risk to discontinue anticoagulation treatment? Results from the GLORIA-AF Registry".EUROPEAN HEART JOURNAL 39.(2018):1007-1007